Pharmaceuticals Trio Draw Buy Ratings Ahead of 2026 Catalysts
A trio of small-cap biotechs—X4 Pharmaceuticals, Immuneering, and Tango Therapeutics—are attracting new and renewed a...
This brief overview contrasts lifecycle funds with target date funds, highlighting key distinctions to help you choose the right fund for retirement planning.
18,693 articlesA trio of small-cap biotechs—X4 Pharmaceuticals, Immuneering, and Tango Therapeutics—are attracting new and renewed a...
Bitcoin has been in the news for years, but the big question remains: is it late to buy? This guide breaks down the r...
Palantir delivered an 85% year-over-year revenue surge in Q1 2026 and lifted full-year targets, but the shares are do...
Nvidia sits at the epicenter of the AI hardware boom. With May 20 on the horizon, investors are weighing whether will...
A Nike brand moat argument resurfaces as investors weigh the stock's downside and potential upside. A Nike analyst po...
Micron Technology has delivered a stunning 770% year-to-date surge as AI-driven memory demand intensifies. The rally ...
Rocket Lab stock remains volatile but disciplined investors see a path to a $150 milestone by 2027 as backlog grows a...
IREN stock surge propels the stock higher as the company pivots to AI cloud infrastructure and signs multi-billion de...
Robinhood stock has shown volatility as July 29 earnings approach. This guide breaks down what matters, how to read t...
A major fund recently disclosed a large move in Globalstar as the stock surged. This article explains what happened, ...
A major fund disclosed a sizable NEU share sale. This article unpacks what the move signals, how to interpret it, and...
A notable fund pulled out of a multi-million dollar DNOW position last quarter, triggering questions about strategy a...